Ex vivo activated immune cells promote survival and stimulate multilineage hematopoietic recovery in myelosuppressed mice

Journal of Immunotherapy

Volumn 28, Issue 4, 2005, Pages 420-425

  Li, Gong ^a   Wang, Xiaohuai ^a   Wu, Lubo ^b   Zhang, Weimin ^a   Chen, Huiyu ^a   Xie, Yongfu ^b   Yang, Demao ^b  

^a Liu Hua Qiao Hospital   (China)

^b Yangfan Biotechnology Corporation   (China)

Author keywords

Chemotherapy; Hematopoiesis; Immunotherapy; Myelosuppression

Indexed keywords

CALCIMYCIN; CALCIUM IONOPHORE; CARBOPLATIN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL ADHESION; CELL LINEAGE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INJECTION; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE;

EID: 21844478265     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000170360.99714.3f     Document Type: Article

References (31)

1. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol. 2003;21:759-806.
2. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control. 2003;10:9-16.
3. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19:1137-1146.
4. Mercadante S, Gebbia V, Marrazzo A, et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26:303-311.
5. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am. 1993;7:771-793.
6. Allegretta GJ, Weisman SJ, Altman A. Oncologic emergencies II. Hematologic and infectious complications of cancer and cancer treatment. Pediatr Clin North Am. 2003;32:613-624.
7. Sieger D, D'Addario G, Lorenz U, et al. Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF in the treatment of patients with advanced ovarian cancer (FIGO III and IV): a phase I study. Inter J Cancer Res Treat. 1999;22:502-506.
8. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000;36(Suppl 1): S11-S14.
9. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(suppl 2): 18-24.
10. Weite K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907-1929.
11. Armitage JO. Emerging applications of recombinant human granulocy temacrophage colony-stimulating factor. Blood. 1998;92:4491-4508.
12. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303-2320.
13. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997;89:3897-3908.
14. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
15. Barnett D, Janossy G, Lubenko A, et al. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Clin Lab Haematol. 1999;21:301-308.
16. Sutherland DR, Keating A, Nayar R, et al. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol. 1994;22:1003-1010.
17. Chen J, Liu W, Wang X, et al. Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematother Stem Cell Res. 2003;12: 505-514.
18. Demao Y. Response. Stem Cells Devel. 2004;13:162-163.
19. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
20. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599-2602.
21. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87: 2095-2147.
22. Peters M, Müller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor, direct stimulation of gp130 and hematopoiesis. Blood. 1998;92: 3495-3504.
23. Youn B, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000;177:150-174.
24. Larsen CS. Activation of human T lymphocytes by phorbol-12,13-dibutyrate and ionomycin. Scand J Immunol. 1990;31:353-360.
25. Slanicka KM, Nissen C, Manz CY, et al. The membrane-bound isoform of stem cell factor synergizes with soluble flu ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow. Exp Hematol. 1998;26:365-373.
26. Davis TA, Robinson DH, Lee KP, et al. Porcine brain microvascular endothelial cells support the in vitro expansion of human primitive hematopoietic bone marrow progenitor cells with a high replating potential: requirement for cell-to-cell interactions and colony-stimulating factors. Blood. 1995;85:1751-1761.
27. Koski GK, Schwartz GN, Weng DE, et al. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood. 1999;94:1359-1371.
28. Bedrosian I, Roros JG, Xu S, et al. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. J Immunother. 2000;23:311-320.
29. Czerniecki BJ, Carter C, Rivoltini L, et al. Calcium ionophore treated human peripheral blood monocytes display characteristics of activated dendritic cells. J Immunol. 1997;159:3823-3837.
30. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998;129:1031-1035.
31. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 2003;48:166-173.